Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | AGXT | P21549 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3622330 | 0.85 | CYP1A2 (0.60) | TAAR1KDM4EALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL2808421 | 0.83 | TAAR1 (0.57) | TAAR1MEN1KMT2AIDO1AGXT | |
| SCHEMBL30739138 | 0.83 | TAAR1 (0.57) | TAAR1MEN1KMT2AIDO1AGXT | |
| SCHEMBL552961 | 0.81 | TAAR1 (0.66) | TAAR1CYP1A2CYP2D6CYP2C19GPR84 | |
| SCHEMBL8209947 | 0.81 | TAAR1 (0.60) | TAAR1KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL10201988 | 0.81 | KDM4E (0.47) | KDM4EALDH1A1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL29602871 | 0.80 | TAAR1 (0.55) | TAAR1KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL553063 | 0.80 | TAAR1 (0.68) | TAAR1CYP1A2CYP2D6CYP2C19GPR84 | |
| SCHEMBL2808674 | 0.80 | TAAR1 (0.53) | TAAR1KDM4ECYP1A2CYP2D6CYP2C19 | |
| SCHEMBL7235032 | 0.79 | GAA (0.65) | TAAR1KDM4EMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577383-B2 | Macrocyclic inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190177340-A1 | MACROCYCLIC INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177340-A1 | MACROCYCLIC INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | TAAR1 4137/4885KDM4E 2722/4885ALDH1A1 364/4885 |
| US-10577383-B2 | Macrocyclic inhibitors of myeloperoxidase | EPX, MPO, SERPINB1 | TAAR1 4137/4885KDM4E 2722/4885ALDH1A1 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.